Pharmacogenomics of Chronic Inflammatory Diseases, Where Are We?

Chronic inflammation is a component of many diseases affecting a large population of the world. It occurs when initiating stimuli are not eliminated, or resolution processes are disrupted, resulting in a low-grade inflammatory state. It is recognized that chronic inflammatory diseases are involved in cardiovascular disease, endocrine disease, neurodegenerative disease, liver disease, lung disease, gastrointestinal disease, and cancer, including but not limited to atherosclerosis, diabetes, multiple sclerosis, fibrosis, nonalcoholic fatty liver, COPD, inflammatory bowel disease, and autoimmune diseases, which are the leading worldwide mortality causes. Therefore, there is a need to explore new targets and therapeutic agents for chronic inflammatory diseases.

Pharmacogenomics can be broadly defined as the study of how genomics relates to each other and how the response to a drug varies for individuals or different individuals. This includes efficacy, dose adjustment, adverse effects, and identifying new drug targets. Pharmacogenomics research has evolved significantly in recent decades due to rapid technological advances. However, it has had limited success in discovering genes corresponding to drug efficacy in chronic inflammatory conditions.

This Research Topic aims to study the pharmacogenomics of chronic inflammatory diseases with a focus on therapeutic agents to discover new therapeutic agents and clinical drugs for treating chronic inflammatory diseases. Combining bioinformatics analysis with basic functional studies of chronic inflammatory diseases can identify potential new drug targets for chronic inflammatory diseases. Therefore, this topic aims to include analyzing pathological mechanisms, evaluating therapeutic agents, screening new drugs based on new targets, constructing novel drug delivery systems, early diagnosis, drug development, and sequencing tools.

In this Research Topic, we welcome original research articles, reviews, opinions, perspectives, and systematic reviews, including but not limited to the following issues：
• Pathophysiological mechanisms and new target studies in chronic inflammatory diseases;
• Elucidation of therapeutic drug mechanisms in chronic inflammatory diseases;
• Discovery of new therapeutic agents for the treatment of chronic inflammatory diseases;
• Drug translation and drug success studies in chronic inflammatory diseases;
• Genome-wide association (GWA) study approach to identify novel genetic variants for drug safety/efficacy in chronic inflammatory diseases.

Please note this Research Topic does not accept publication studies carried out on natural compounds, herbal extracts, or traditional medicine products, and only the use of highly purified, chemically characterized compounds is acceptable.